December 15, 2022 (v1)
Publication
No description
Uploaded on: March 24, 2023
-
-
May 31, 2023 (v1)Publication
Background: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the...
Uploaded on: June 2, 2023 -
January 20, 2023 (v1)Publication
Although the overall survival of advanced soft-tissue sarcoma (STS) patients has increased in recent years, the median progression-free survival is lower than 5 months, meaning that there is an unmet need in this population. Among second-line treatments for advanced STS, eribulin is an anti-microtubule agent that has been approved for...
Uploaded on: March 24, 2023